Daiichi Sankyo Announces Discontinuation of Development of Nafamostat Inhalation Formulation (DS-2319) in Japan

Tokyo, Japan - (June 15, 2021) – Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) today announced that it has decided to discontinue development of nafamostat inhalation formulation (DS-2319) for treatment of the novel coronavirus infectious disease (COVID-19).

DS-2319 is a drug product in inhalation dosage form that contains nafamostat mesilate (hereinafter, nafamostat). Daiichi Sankyo proceeded with its development, expecting that nafamostat might exert a therapeutic effect by blocking membrane fusion between the envelope of the virus that causes COVID-19 and the host plasma cell membrane, and initiated a phase 1 trial in March 2021.

In view of situations of ongoing non-clinical studies and the phase 1 trial, however, Daiichi Sankyo has decided to discontinue the development of DS-2319.

Daiichi Sankyo will continue making efforts to enhance public health and prevent and treat diseases through the manufacture and supply of pharmaceutical products, including vaccines, thereby contributing to promoting the health of the Japanese people.

About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.